



Zymeworks Appoints Noel Hall to Its Board of Directors

November 3rd, 2008

VANCOUVER, British Columbia, Canada – Zymeworks Inc., a privately held computational biotechnology company, today announced the appointment of Noel Hall to its board of directors. Mr. Hall’s extensive knowledge of the biotechnology industry, along with his business-building experience, will significantly contribute to Zymeworks’ growth by guiding the development of its therapeutics pipeline.

Noel Hall is a consultant to the life sciences industry with over 25 years of experience in the biotechnology sector. He was the Co-founder, President, and Director of Aspreva Pharmaceuticals, which was acquired by the Galenica Group in January 2008. Prior to Aspreva, Mr. Hall co-founded the life sciences practice of consulting firm Hill and Knowlton and served as Head of Global Strategic Planning for the firm’s worldwide pharmaceutical consulting practice. Mr. Hall was the Director of Corporate Affairs for the United Kingdom and Northern Europe for The Wellcome Foundation Ltd., which is now part of GlaxoSmithKline PLC. Additionally, Mr. Hall worked in market development with Abbott Laboratories Ltd. and was the regional sales manager with Leo Laboratories Ltd. Mr. Hall holds a B.Sc. degree in Medical Laboratory Science from London University, and currently serves on the board of directors of iCo Therapeutics Inc.

“We are extremely pleased to welcome Mr. Hall to our board of directors,” says Dr. Ali Tehrani, President and CEO of Zymeworks. “His unique combination of industry insight and experience will be a tremendous asset to Zymeworks as we continue to advance towards a protein therapeutics pipeline and expand on our strategic collaborations in the pharmaceutical and chemical sectors.”

About Zymeworks Inc.

Zymeworks is a computational biotechnology company that combines proprietary molecular simulation technology with high performance computing to research and develop protein therapeutics and industrial enzymes. Zymeworks’ proprietary ZymeCAD™ molecular simulation platform creates a highly detailed modeling environment that generates novel physical and chemical insights into protein systems. Zymeworks’ protein engineers utilize these new understandings into structure-function relationships to accurately modify proteins to address customers’ needs and to advance Zymeworks’ protein therapeutics pipeline. More information on Zymeworks can be found at <http://www.zymeworks.com>.

Contact:

Zymeworks Inc.
Ali Tehrani, President and CEO
info@zymeworks.com
Source: Zymeworks Inc.